We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Minerva Presents Additional Data from Schizophrenia Drug
Read MoreHide Full Article
Minerva Neurosciences, Inc. (NERV - Free Report) announced the results of additional data analyses from phase IIb study of MIN-101, as monotherapy in patients with negative symptoms of schizophrenia.
Minerva’s share price has gained 98.5% in the past one year, while the Zacks classified Medical-Drugs industry witnessed a fall of 13.1%.
Coming back to the latest release, the additional data showed significant improvements in several sub-tests of cognitive functioning, including motor tests and verbal fluency in patients with schizophrenia. Deficits in these capabilities are associated with poor interpersonal and real-world functioning for these patients.
Cognitive impairment is a core feature of schizophrenia, which affects up to 75% of the patients population. Earlier in May 2016, the company announced top-line results from 12-week core phase of the study that showed that the study met its primary endpoint – the patients experienced statistically significant improvement of negative symptoms when treated with MIN-101 as compared to placebo. Statistically significant benefit of MIN-101 was also demonstrated in multiple secondary endpoints.
Further in Oct 2016, Minerva announced data from the 24-week open-label extension of its 12-week, phase IIb study of MIN-101. Data from the extension phase demonstrated a further and continuous improvement in negative symptoms in patients with schizophrenia.
Minerva's other pipeline candidates, include MIN-117 which is in clinical development for major depressive disorder (MDD), MIN-202 which is in clinical development for insomnia and MDD; and MIN-301 which is in pre-clinical development for Parkinson's disease.
Zacks Rank & Key Picks
Minerva currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include Enzo Biochem, Inc. (ENZ - Free Report) , Sunesis Pharmaceuticals, Inc. and Anika Therapeutics Inc. (ANIK - Free Report) . While Enzo Biochem sports a Zacks Rank #1 (Strong Buy), Sunesis and Anika carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Enzo Biochem’s loss estimates for 2017 narrowed 5.88% over the past 60 days. The company recorded a positive earnings surprise in three of the last four quarters, the average being 22.50%. Its share price was up 44.9% in the past one year.
Sunesis’ loss estimates narrowed 5.06% and 8.80% for 2017 and 2018, respectively, over the past 60 days. The company recorded a positive earnings surprise in three of the last four quarters, the average being 0.54%.
Anika’s earnings estimates for 2016 and 2017 were up 3.9% and 0.5%, respectively, over the last 60 days. The company recorded a positive earnings surprise in each of the last four quarters, the average being 37.8%. Its share price was up 36% in the past one year.
How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Minerva Presents Additional Data from Schizophrenia Drug
Minerva Neurosciences, Inc. (NERV - Free Report) announced the results of additional data analyses from phase IIb study of MIN-101, as monotherapy in patients with negative symptoms of schizophrenia.
Minerva’s share price has gained 98.5% in the past one year, while the Zacks classified Medical-Drugs industry witnessed a fall of 13.1%.
Coming back to the latest release, the additional data showed significant improvements in several sub-tests of cognitive functioning, including motor tests and verbal fluency in patients with schizophrenia. Deficits in these capabilities are associated with poor interpersonal and real-world functioning for these patients.
Cognitive impairment is a core feature of schizophrenia, which affects up to 75% of the patients population. Earlier in May 2016, the company announced top-line results from 12-week core phase of the study that showed that the study met its primary endpoint – the patients experienced statistically significant improvement of negative symptoms when treated with MIN-101 as compared to placebo. Statistically significant benefit of MIN-101 was also demonstrated in multiple secondary endpoints.
Further in Oct 2016, Minerva announced data from the 24-week open-label extension of its 12-week, phase IIb study of MIN-101. Data from the extension phase demonstrated a further and continuous improvement in negative symptoms in patients with schizophrenia.
Minerva's other pipeline candidates, include MIN-117 which is in clinical development for major depressive disorder (MDD), MIN-202 which is in clinical development for insomnia and MDD; and MIN-301 which is in pre-clinical development for Parkinson's disease.
Zacks Rank & Key Picks
Minerva currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include Enzo Biochem, Inc. (ENZ - Free Report) , Sunesis Pharmaceuticals, Inc. and Anika Therapeutics Inc. (ANIK - Free Report) . While Enzo Biochem sports a Zacks Rank #1 (Strong Buy), Sunesis and Anika carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Enzo Biochem’s loss estimates for 2017 narrowed 5.88% over the past 60 days. The company recorded a positive earnings surprise in three of the last four quarters, the average being 22.50%. Its share price was up 44.9% in the past one year.
Sunesis’ loss estimates narrowed 5.06% and 8.80% for 2017 and 2018, respectively, over the past 60 days. The company recorded a positive earnings surprise in three of the last four quarters, the average being 0.54%.
Anika’s earnings estimates for 2016 and 2017 were up 3.9% and 0.5%, respectively, over the last 60 days. The company recorded a positive earnings surprise in each of the last four quarters, the average being 37.8%. Its share price was up 36% in the past one year.
Minerva Neurosciences Inc. Price
Minerva Neurosciences Inc. Price | Minerva Neurosciences Inc. Quote
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>